ESPE2024 Poster Category 1 Bone, Growth Plate and Mineral Metabolism 3 (10 abstracts)
Safety and efficacy of continuous subcutaneous PTH (1-34) infusion therapy (CSPI) for severe autosomal dominant hypocalcaemia type 1 (ADH1) in Children and Young People (CYP)
Aikaterini Perogiannaki* 1 , Mohammad Meshari Alattar* 1 , Kishore Baske 1 , Rebecca J. Gorrigan 2 , Oladimeji Smith 3 , Debbie Pullen 4 , Sailesh Sankaranarayanan 5 , Jeremy Allgrove 6 & Evelien Gevers 7,1
1Barts Health NHS Trust, Royal London Hospital, Department of Paediatric Endocrinology, London, United Kingdom. 2Barts Health NHS Trust, Royal London Hospital, Department of Endocrinology, London, United Kingdom. 3East Kent Hospitals University NHS Foundation Trust, William Harvey Hospital, Ashford, United Kingdom. 4Surrey and Sussex Healthcare NHS Trust, East Surrey Hospital, Redhill, United Kingdom. 5University Hospitals Coventry and Warwickshire Coventry, Coventry, United Kingdom. 6Great Ormond Street Hospital for Children London, London, United Kingdom. 7Queen Mary University of London, Barts and the London Medical School, William Harvey Research Institute, Centre for Endocrinology, London, United Kingdom
*Aikaterini Perogiannaki and Mohammad Meshari Alattar are joint first authors of this work.
Introduction: ADH1 is caused by Calcium Sensing Receptor (CaSR) gain of function (GoF) variants, leading to hypoparathyroidism, hypocalcaemia, seizures, hyperphosphatemia, hypomagnesaemia and severe hypercalciuria. Conventional treatment (Alphacalcidol, Calcium) predisposes to nephrocalcinosis and renal impairment and may not reduce seizures. We previously reported that CSPI by insulin pump effectively increased serum calcium concentrations and reduced seizures, hospital admissions and calcium excretion in six patients with severe ADH1 (mean CSPI duratio n = 3.2±0.6 years). We now report longer-term data on the CSPI safety and efficacy.
Methods: Retrospective observational study of five ADH1 patients (age 6-30 years) treated with CSPI (mean duratio n = 8.22±1.26years). The sixth had renal and parathyroid transplantation and stopped CSPI. All had GoF CASR variants and recurrent hypocalcaemic seizures requiring hospital admission on conventional treatment or PTH injections prior to CSPI. Effects on seizure frequency, growth, bone mineral density and hospital admissions were assessed. Six-monthly serum and urine mineral concentrations were collected from the end of the previous collection period (Jan 2018) and mean and SD are presented.
Results: Effect of CSPI treatment over 5.99-9.01 years is shown in the table below.
NR: Normal range *Latest value **Data expressed as: Mean±SD (Minimum, Maximum)
| Patient(P) | P1 | P2 | P3 | P4 | P5 |
| CASR Variant | p.F821L | p.T828N | p.T828N | p.Y829C | p.A843E |
| Current Age(Years) | 8.77 | 9.43 | 30.86 | 9.15 | 6.23 |
| CSPI Duration(Years) | 8.67 | 8.58 | 8.86 | 9.01 | 5.99 |
| CSPI Dose[mcg/kg/day]* | 0.63 | 0.28 | 0.6 | 0.29 | 0.56 |
| Adjusted Calcium[mmol/L](NR:2.2-2.6)** | 1.98±0.31(1.55,2.71) | 1.94±0.36(1.49,2.57) | 1.90±0.20(1.7,2.35) | 2.06±0.28(1.41,2.48) | 2.27±0.22(1.89,2.6) |
| Calcium-Phosphate Product** | 3.50±0.51(2.57,4.30) | 3.91±0.41(3.13,4.27) | 2.34±0.33(1.91,2.91) | 4.18±0.58(3.27,5.45) | 4.48±0.56(3.73,5.52) |
| Urine Calcium/Creatinine Ratio** | 1.12±0.61(0.48,2.50) | 0.74±0.29(0.27,1.19) | 0.58±0.23(0.21,0.87) | 0.49±0.21(0.13,0.74) | 0.45±0.31(0.14, 1.00) |
| 24-hour Urinary Calcium[mmol/day](NR:2.5-7.5)** | 4.5±1.06(3.1,5.6) | 2.0±1.85(1.4,2.6) | 2.82±0.88(2.2,3.44) | 1.7±0.95(0.8,2.7) | NA |
| Admissions for Hypocalcaemia(Days) | 21 | 3 | 7 | 0 | 3 |
| Hypocalcaemic Seizures | 0 | 1 | 1 | 0 | 0 |
| Height(SDS)* | 126.6(-0.73) | 132.9(-0.41) | 145.1(-3.06) | 134.6(0.09) | 124.9(1.67) |
| BMD L1-L4 Z Score* | -1.4 | -0.5 | NA | 0.3 | 0.3 |
| Nephrocalcinosis | Early nephrocalcinosis | Stable | Stable | None | None |
| Treatment Emergent Adverse Events | Autoimmune Hypothyroidism | Frequent Vomiting | Anxiety and depression | Dental issues, Central Precocious puberty | |
| None of the patients that started CSPI before the age of 1 year had a learning disability. | |||||
Conclusion: CSPI remains a safe long-term option for CYP with ADH1, maintaining serum calcium, ameliorating seizures and reducing hospital admissions. Importantly, calcium excretion and BMD remains normal, and only one patient developed new mild nephrocalcinosis. It is currently not known whether the TEAEs are related to CSPI. In conclusion, these data suggest that, without other effective treatments, CSPI is a safe and effective option for severe ADH1.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more